Novel cardiovascular disease (CVD) risk factors elevated in young women with PCOS – possible link between NEFA and androgens identified

Abstract

ObjectiveWomen with polycystic ovary syndrome (PCOS) have increased evidence of subclinical and clinical atherosclerosis. Early diagnosis will allow timely implementatoin of preventive strategies. Our objective was to identify novel CVD biomarkers for risk stratification in reproductive age women with PCOS.DesignCross sectional study.Materials and MethodsWomen with PCOS (NICHD definition) and geographically matched controls were recruited. Serum lipid biomarkers, non-esterified fatty acids (NEFA, key mediator of visceral adipose tissue mediated endothelial cell activation) and angiopoetin-like proteins (ANGPTL) 3 and 4 (important role in lipid metabolism) were measured.ResultsTabled 1CV disease biomarkers in women with PCOS and controlsPCOS (n=124)Controls (n=67)Age yrs28.4±6.131.9±6.9Testosteroe ng/dl53.2±43.431.26±17.1**Systolic BP124.4±12108.2±13.6**Diastolic BP72.5±7.767.6±8.3**BMI33.1±7.629.0±7.1**LDL-C mg/dl167.1±50.1154.1±44TG mg/dl146.5±92.9122.2±69.9ApoB/A10.5±0.20.48±0.16**ApoC314.0±6.113.5±6.7NEFA0.6±0.30.43±0.2**ANGPLT-3180.1±66.2179.5±76.2ANGPLT-4162.5±88.9155.5±94.2*P<0.05, **P<0.01. Open table in a new tab ConclusionNEFA and ApoB/A1 may serve as candidate CVD biomarkers to risk stratify women with PCOS. Longitudinal studies will better assess the potential use of these biomarkers in PCOS. In additon, our data suggests that PCOS is a unique model to examine the causal relationship between NEFA and androgens. ObjectiveWomen with polycystic ovary syndrome (PCOS) have increased evidence of subclinical and clinical atherosclerosis. Early diagnosis will allow timely implementatoin of preventive strategies. Our objective was to identify novel CVD biomarkers for risk stratification in reproductive age women with PCOS. Women with polycystic ovary syndrome (PCOS) have increased evidence of subclinical and clinical atherosclerosis. Early diagnosis will allow timely implementatoin of preventive strategies. Our objective was to identify novel CVD biomarkers for risk stratification in reproductive age women with PCOS. DesignCross sectional study. Cross sectional study. Materials and MethodsWomen with PCOS (NICHD definition) and geographically matched controls were recruited. Serum lipid biomarkers, non-esterified fatty acids (NEFA, key mediator of visceral adipose tissue mediated endothelial cell activation) and angiopoetin-like proteins (ANGPTL) 3 and 4 (important role in lipid metabolism) were measured. Women with PCOS (NICHD definition) and geographically matched controls were recruited. Serum lipid biomarkers, non-esterified fatty acids (NEFA, key mediator of visceral adipose tissue mediated endothelial cell activation) and angiopoetin-like proteins (ANGPTL) 3 and 4 (important role in lipid metabolism) were measured. ResultsTabled 1CV disease biomarkers in women with PCOS and controlsPCOS (n=124)Controls (n=67)Age yrs28.4±6.131.9±6.9Testosteroe ng/dl53.2±43.431.26±17.1**Systolic BP124.4±12108.2±13.6**Diastolic BP72.5±7.767.6±8.3**BMI33.1±7.629.0±7.1**LDL-C mg/dl167.1±50.1154.1±44TG mg/dl146.5±92.9122.2±69.9ApoB/A10.5±0.20.48±0.16**ApoC314.0±6.113.5±6.7NEFA0.6±0.30.43±0.2**ANGPLT-3180.1±66.2179.5±76.2ANGPLT-4162.5±88.9155.5±94.2*P<0.05, **P<0.01. Open table in a new tab *P<0.05, **P<0.01. ConclusionNEFA and ApoB/A1 may serve as candidate CVD biomarkers to risk stratify women with PCOS. Longitudinal studies will better assess the potential use of these biomarkers in PCOS. In additon, our data suggests that PCOS is a unique model to examine the causal relationship between NEFA and androgens. NEFA and ApoB/A1 may serve as candidate CVD biomarkers to risk stratify women with PCOS. Longitudinal studies will better assess the potential use of these biomarkers in PCOS. In additon, our data suggests that PCOS is a unique model to examine the causal relationship between NEFA and androgens.